233 related articles for article (PubMed ID: 36651217)
1. International consortium for innovation and quality: An industry perspective on the nonclinical and early clinical development of intravitreal drugs.
Pruimboom-Brees IM; Gupta S; Chemuturi N; Booler HS; Nimz E; Ferrell Ramos M; Caruso A; Maass KF; Bantseev V; Huang Q; Choules MP; Nussbaum JC; Kanodia J; Thompson C; Durairaj C
Clin Transl Sci; 2023 May; 16(5):723-741. PubMed ID: 36651217
[TBL] [Abstract][Full Text] [Related]
2. Posterior subtenon and intravitreal triamcinolone acetonide for diabetic macular edema.
Ozdek S; Bahçeci UA; Gürelik G; Hasanreisoğlu B
J Diabetes Complications; 2006; 20(4):246-51. PubMed ID: 16798476
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal bevacizumab alone or combined with 1 mg triamcinolone in diabetic macular edema: a randomized clinical trial.
Riazi-Esfahani M; Riazi-Esfahani H; Ahmadraji A; Karkhaneh R; Mahmoudi A; Roohipoor R; Ghasemi F; Yaseri M
Int Ophthalmol; 2018 Apr; 38(2):585-598. PubMed ID: 28349504
[TBL] [Abstract][Full Text] [Related]
4. A randomized, dose-escalation study of subconjunctival and intravitreal injections of sirolimus in patients with diabetic macular edema.
Dugel PU; Blumenkranz MS; Haller JA; Williams GA; Solley WA; Kleinman DM; Naor J
Ophthalmology; 2012 Jan; 119(1):124-31. PubMed ID: 22115710
[TBL] [Abstract][Full Text] [Related]
5. Preclinical challenges for developing long acting intravitreal medicines.
Awwad S; Henein C; Ibeanu N; Khaw PT; Brocchini S
Eur J Pharm Biopharm; 2020 Aug; 153():130-149. PubMed ID: 32445965
[TBL] [Abstract][Full Text] [Related]
6. Safety of intravitreal triamcinolone and its impact on optic nerve morphology in patients treated for diabetic macular edema.
Carreira AR; Marques N; Carreira P; Moraes F; Loureiro T; Telles Freitas P; Cardoso J; Campos N
Eur J Ophthalmol; 2022 May; 32(3):1596-1601. PubMed ID: 34176301
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal bevacizumab versus intravitreal triamcinolone for diabetic macular edema-Systematic review, meta-analysis and meta-regression.
Abdel-Maboud M; Menshawy E; Bahbah EI; Outani O; Menshawy A
PLoS One; 2021; 16(1):e0245010. PubMed ID: 33434220
[TBL] [Abstract][Full Text] [Related]
8. Dexamethasone Intravitreal Implant Injection in Eyes with Comorbid Hypotony.
Kong X; Psaras C; Stewart JM
Ophthalmol Retina; 2019 Nov; 3(11):993-997. PubMed ID: 31371197
[TBL] [Abstract][Full Text] [Related]
9. [Evaluation of intravitreal injection practice patterns in Cotonou].
Agbahoungba L; Alamou S; Abouki C; Djossou-Doutetien A; Lawani R; Tchabi S
J Fr Ophtalmol; 2018 Dec; 41(10):963-967. PubMed ID: 30470487
[TBL] [Abstract][Full Text] [Related]
10. Systemic exposure following intravitreal administration of therapeutic agents: an integrated pharmacokinetic approach. 2. THR-687.
Vanhove M; Wagner JM; Noppen B; Jonckx B; Vermassen E; Stitt AW
J Pharmacokinet Pharmacodyn; 2021 Dec; 48(6):837-849. PubMed ID: 34302261
[TBL] [Abstract][Full Text] [Related]
11. Pharmacology of Corticosteroids for Diabetic Macular Edema.
Whitcup SM; Cidlowski JA; Csaky KG; Ambati J
Invest Ophthalmol Vis Sci; 2018 Jan; 59(1):1-12. PubMed ID: 29297055
[TBL] [Abstract][Full Text] [Related]
12. Real-world outcomes following 12 months of intravitreal aflibercept monotherapy in patients with diabetic macular edema in France: results from the APOLLON study.
Korobelnik JF; Daien V; Faure C; Tadayoni R; Giocanti-Auregan A; Dot C; Kodjikian L; Massin P
Graefes Arch Clin Exp Ophthalmol; 2020 Mar; 258(3):521-528. PubMed ID: 31894377
[TBL] [Abstract][Full Text] [Related]
13. Hypertensive cerebral hemorrhage with undetectable plasma vascular endothelial growth factor levels in a patient receiving intravitreal injection of aflibercept for bilateral diabetic macular edema: a case report.
Yoshimoto M; Takeda N; Yoshimoto T; Matsumoto S
J Med Case Rep; 2021 Jul; 15(1):403. PubMed ID: 34311786
[TBL] [Abstract][Full Text] [Related]
14. Comparison of intravitreal bevacizumab alone or combined with triamcinolone versus triamcinolone in diabetic macular edema: a randomized clinical trial.
Lim JW; Lee HK; Shin MC
Ophthalmologica; 2012; 227(2):100-6. PubMed ID: 21997197
[TBL] [Abstract][Full Text] [Related]
15. [Effects of Intravitreal Injection of Anti-vascular Endothelial Growth Factor Drugs on Ocular Blood Vessels and Blood Flow in Patients with Diabetic Retinopathy].
Huang H; Shi L; Li S; Wu N; Rao J; Wu YJ; Wu XR
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2021 Oct; 43(5):796-800. PubMed ID: 34728042
[TBL] [Abstract][Full Text] [Related]
16. Systemic exposure following intravitreal administration of therapeutic agents: an integrated pharmacokinetic approach. 1. THR-149.
Vanhove M; Noppen B; Wagner JM; Van Bergen T; Barbeaux P; Stitt AW
J Pharmacokinet Pharmacodyn; 2021 Dec; 48(6):825-836. PubMed ID: 34302260
[TBL] [Abstract][Full Text] [Related]
17. [Complications of intravitreal injections--own experience].
Jamrozy-Witkowska A; Kowalska K; Jankowska-Lech I; Terelak-Borys B; Nowosielska A; Grabska-Liberek I
Klin Oczna; 2011; 113(4-6):127-31. PubMed ID: 21913440
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal bevacizumab with or without triamcinolone acetonide for diabetic macular edema: a meta-analysis of randomized controlled trials.
Liu X; Zhou X; Wang Z; Li T; Jiang B
Chin Med J (Engl); 2014; 127(19):3471-6. PubMed ID: 25269916
[TBL] [Abstract][Full Text] [Related]
19. Exploratory analysis of the effect of intravitreal ranibizumab or triamcinolone on worsening of diabetic retinopathy in a randomized clinical trial.
Bressler SB; Qin H; Melia M; Bressler NM; Beck RW; Chan CK; Grover S; Miller DG;
JAMA Ophthalmol; 2013 Aug; 131(8):1033-40. PubMed ID: 23807371
[TBL] [Abstract][Full Text] [Related]
20. Widening use of dexamethasone implant for the treatment of macular edema.
Bonfiglio V; Reibaldi M; Fallico M; Russo A; Pizzo A; Fichera S; Rapisarda C; Macchi I; Avitabile T; Longo A
Drug Des Devel Ther; 2017; 11():2359-2372. PubMed ID: 28860707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
